Viscosupplementation Market to Reach US$13.85 Billion by 2035, Driven by Rising Osteoarthritis Prevalence and Minimally Invasive Treatments

The global Viscosupplementation Market was valued at USD 5,871.24 million in 2025 and is estimated to reach USD 13,848.44 million by 2035, growing at a CAGR of 8.96% during the forecast period 2026-2035. The market is gaining momentum as the increasing prevalence of osteoarthritis, an aging population, and growing demand for minimally invasive joint pain management continue to support the adoption of viscosupplementation therapies. Rising preference for non-surgical treatment options, improvements in hyaluronic acid formulations, and increasing awareness of joint-care therapies are further contributing to market expansion.

The competitive opportunity is increasingly focused on advanced hyaluronic acid formulations, improved treatment durability, patient convenience, and minimally invasive therapies. Manufacturers are investing in products designed to provide longer-lasting symptom relief and improve joint function while reducing the need for invasive surgical interventions. The market is therefore shifting toward innovative viscosupplementation formulations, single-injection therapies, personalized treatment approaches, and improved osteoarthritis management, supporting sustained growth in the global Viscosupplementation Market through 2035.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/viscosupplementation-market?sai-v

Recent Developments
August 2026: North America continued leading the viscosupplementation market, supported by a large osteoarthritis patient population, established orthopedic-care infrastructure, and increasing availability of hyaluronic-acid-based products. The region accounted for 45.38% of global market revenue in 2025.

July 2026: Asia-Pacific continued recording strong growth, supported by an aging population, rising osteoarthritis prevalence, improving orthopedic-care access, and increasing adoption of non-surgical joint-pain treatments across China, Japan, India, and South Korea. China and Japan are projected to record particularly strong growth rates.

June 2026: Europe continued expanding viscosupplementation adoption as healthcare providers increasingly emphasized non-surgical management of osteoarthritis. The European market reached USD 0.88 billion in 2025, supported by rising osteoarthritis prevalence and product introductions.

May 2026: Manufacturers increasingly focused on single-injection formulations, high-molecular-weight hyaluronic acid, non-animal products, and next-generation viscosupplements to improve convenience, treatment adherence, and patient outcomes. The single-injection segment is projected to account for 60.16% of the market in 2026.

April 2026: The global market continued benefiting from the growing burden of knee osteoarthritis and demand for minimally invasive treatment options. Recent product development has emphasized longer-lasting formulations and reduced injection frequency, while orthopedic clinics and ambulatory care settings remain important treatment channels.

Key Players

Anika Therapeutics, Inc. | Seikagaku Corporation | Bioventus Inc. | Johnson & Johnson | Zimmer Biomet | Sanofi S.A. | Miravo Healthcare | Aptissen | LG Chem and Life Sciences Ltd. | F. Hoffmann-La Roche Ltd. | Others

Key Highlights
Anika Therapeutics, Inc. - Holds a 4.0% share, supported by its hyaluronic acid-based viscosupplementation portfolio, orthopedic expertise, and focus on joint preservation and osteoarthritis treatment.

Seikagaku Corporation - Holds a 12.0% share, driven by its hyaluronic acid therapeutics, viscosupplementation products, manufacturing capabilities, and established presence in the osteoarthritis treatment market.

Bioventus Inc. - Holds a 9.0% share, supported by its orthopedic therapies, viscosupplementation portfolio, and focus on improving mobility and joint health.

Johnson & Johnson - Holds a 6.0% share, strengthened by its broad orthopedic and healthcare portfolio and presence in injectable and joint-care treatment solutions.

Zimmer Biomet - Holds an 8.0% share, driven by its strong orthopedic franchise, global distribution network, and established viscosupplementation presence.

Sanofi S.A. - Holds a 15.0% share, supported by its established pharmaceutical portfolio and strong position in viscosupplementation and osteoarthritis treatment.

Miravo Healthcare - Holds a 3.0% share, supported by its specialty healthcare portfolio and focus on products addressing pain and musculoskeletal conditions.

Aptissen - Holds a 3.0% share, driven by its hyaluronic acid-based injectable therapies and focus on osteoarthritis and joint-care applications.

LG Chem and Life Sciences Ltd. - Holds a 5.0% share, strengthened by its hyaluronic acid-based viscosupplementation products and expansion across international markets.

F. Hoffmann-La Roche Ltd. - Holds a 2.0% share, supported by its pharmaceutical and biotechnology capabilities and participation in the broader viscosupplementation market.

Others - Hold a combined 36.0% share, comprising Fidia Farmaceutici, Ferring Pharmaceuticals, Smith & Nephew, OrthogenRx, Teva Pharmaceutical Industries, Chugai Pharmaceutical, and other regional and specialty viscosupplementation providers.

Get the Full Report Here: https://www.datamintelligence.com/buy-now-page?report=viscosupplementation-market?sai-v

Market Drivers
- Rising prevalence of osteoarthritis, particularly knee osteoarthritis, increasing demand for viscosupplementation therapies.

- Growing aging population and increasing incidence of age-related joint degeneration, supporting demand for non-surgical joint pain management.

- Increasing preference for minimally invasive treatment options that can provide pain relief and improve joint mobility.

- Growing adoption of hyaluronic acid-based injections for managing osteoarthritis-related pain and improving joint function.

- Increasing number of patients seeking alternatives to surgery and long-term pharmacological pain management.

- Rising healthcare expenditure and expanding access to orthopedic, rheumatology, and pain-management services.

- Growing research and development activities focused on improving hyaluronic acid formulations, injection technologies, treatment duration, and patient outcomes.

Industry Developments
- Development of advanced hyaluronic acid formulations, including high-molecular-weight and cross-linked products designed to improve treatment durability and clinical performance.

- Increasing introduction of single-injection and extended-duration viscosupplementation products to improve patient convenience and treatment adherence.

- Strategic collaborations between pharmaceutical companies, biotechnology firms, medical device manufacturers, and orthopedic healthcare providers to advance joint-care solutions.

- Growing clinical research evaluating viscosupplementation in combination with physical therapy, pain-management approaches, and other osteoarthritis treatments.

- Increasing development of advanced injection and delivery technologies designed to improve precision, patient comfort, and therapeutic outcomes.

- Expansion of viscosupplementation applications across knee, hip, shoulder, and other joints affected by osteoarthritis and degenerative conditions.

Regional Insights
North America - 41% share: "Driven by the high prevalence of osteoarthritis, aging population, advanced orthopedic care infrastructure, strong adoption of minimally invasive treatments, and significant healthcare expenditure."

Europe - 30% share: "Supported by an aging population, established orthopedic and rheumatology services, increasing demand for non-surgical osteoarthritis treatments, and growing adoption of hyaluronic acid therapies."

Asia Pacific - 23% share: "Fueled by rapid population aging, rising osteoarthritis prevalence, improving healthcare infrastructure, increasing healthcare expenditure, and expanding access to advanced joint-care treatments."

Latin America - 4% share: "Supported by increasing musculoskeletal disease burden, improving orthopedic healthcare services, growing awareness of minimally invasive treatments, and expanding access to viscosupplementation."

Middle East & Africa - 2% share: "Driven by improving healthcare infrastructure, rising prevalence of degenerative joint conditions, increasing access to orthopedic services, and growing adoption of advanced osteoarthritis treatments."

Speak to our analyst and get customization in the report as per your requirements: https://www.datamintelligence.com/customize/viscosupplementation-market?sai-v

Key Segments
➥ By Procedure Type

Single Injection: Represents the dominant and growing segment, driven by patient convenience, reduced treatment visits, shorter treatment schedules, and increasing adoption of single-injection viscosupplementation therapies for osteoarthritis management.

Three Injection: Represents a significant segment, supported by established clinical use, repeated intra-articular treatment protocols, and continued demand for viscosupplementation among patients seeking sustained joint pain relief.

Five Injection: Represents an important segment, fueled by its established role in multi-dose viscosupplementation treatment and continued use for patients requiring a longer course of intra-articular therapy.

➥ By Application

Knee Osteoarthritis: Represents the dominant segment, driven by the high prevalence of knee osteoarthritis, increasing joint pain and mobility concerns, and widespread use of viscosupplementation for symptom management.

Hip Osteoarthritis: Represents a significant segment, supported by increasing prevalence of hip osteoarthritis and growing interest in minimally invasive approaches for managing pain and improving joint function.

Shoulder Osteoarthritis: Represents a growing segment, fueled by increasing recognition of shoulder osteoarthritis and demand for non-surgical treatment options aimed at reducing pain and improving mobility.

Ankle Osteoarthritis: Represents an emerging segment, supported by increasing adoption of intra-articular therapies and the need for non-surgical management of ankle pain and joint degeneration.

➥ By End-User

Orthopedic Clinics: Represents the dominant segment, driven by the specialized nature of viscosupplementation procedures, increasing availability of orthopedic services, and growing preference for outpatient joint-care treatments.

Hospitals: Represents a significant segment, supported by comprehensive orthopedic departments, availability of specialized healthcare professionals, and treatment of patients with moderate-to-severe osteoarthritis and complex joint conditions.

Ambulatory Surgical Centres: Represents a growing segment, fueled by the increasing shift toward outpatient orthopedic procedures, shorter treatment times, cost efficiency, and patient preference for convenient treatment settings.

Explore Report Here:https://www.datamintelligence.com/research-report/viscosupplementation-market

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.